このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) (Aurora)

2026年7月8日 更新者:Lu Huaiwu、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

A Prospective, Open-label, Randomized, Controlled, Non-inferiority Phase II Study Comparing HAL-PDT With Deferred Surgery Versus Immediate Surgery in Subjects With High-grade Squamous Intraepithelial Lesions (HSIL)

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention. This Phase II study aims to comprehensively evaluate the efficacy, safety, and impact on quality of life of hexaminolevulinate photodynamic therapy (HAL-PDT) with deferred surgery compared to immediate surgical treatment in subjects with HSIL.

This is a prospective, open-label, randomized, controlled, non-inferiority trial. A total of 230 subjects are planned to be enrolled, with 115 subjects allocated to each treatment group (HAL-PDT with Deferred Surgery or Immediate Surgery ).

The primary endpoint is the pathological regression rate at 12 months, defined as histological findings of normal tissue or low-grade squamous intraepithelial lesions (LSIL) via colposcopy-directed biopsy. Key secondary endpoints include Human Papillomavirus (HPV) clearance rates at 6 and 12 months, pathological regression rate at 6 months, quality of life assessed by the EORTC QLQ-CX24 questionnaire, safety profiles (incidence, severity, and duration of AEs and SAEs, as well as their relationship to the study treatments), and the proportion of subjects developing cervical cancer within 12 months.

調査の概要

詳細な説明

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are well-established precursors to invasive cervical cancer. Immediate excisional procedures such as loop electrosurgical excision procedure (LEEP) or cold knife conization remain the standard of care; however, they are associated with significant long-term morbidities, including cervical stenosis, cervical incompetence, and adverse obstetric outcomes in women of childbearing age. Hexaminolevulinate photodynamic therapy (HAL-PDT) is a non-invasive, tissue-preserving modality that offers a potential alternative.

This Phase II trial is designed to test the hypothesis that HAL-PDT (HAL-PDT Q2W×6 ) with deferred surgery achieves a 12-month pathological regression rate non-inferior to that of immediate surgery, while providing a favorable safety and quality-of-life profile.

A total of 230 subjects are planned for enrollment, with 115 allocated to each treatment arm. The primary efficacy analysis will be performed on both the Intention-to-Treat (ITT) and Per-Protocol (PP) populations to test the non-inferiority margin, which is pre-specified based on clinically acceptable thresholds. Safety analyses will be conducted on the Safety Set (SS).

研究の種類

介入

入学 (推定)

230

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Fujian
      • Fuzhou、Fujian、中国、350001
        • Fujian Medical University Union Hospital
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:0591-83357896
          • メール:fjxhe_irb@163.com
        • 主任研究者:
          • Dezhao Chen, MD, PhD
      • Fuzhou、Fujian、中国、350005
        • The First Affiliated Hospital of Fujian Medical University
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:0591-87982001
          • メール:fdyy_irb@163.com
        • 主任研究者:
          • Lihong Chen, MD, PhD
      • Xiamen、Fujian、中国、361001
        • Xiamen Maternity and Child Healthcare Hospital
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:0592-2662920
          • メール:xmfyllwyh@163.com
        • 主任研究者:
          • Qing Li, MD, PHD
      • Xiamen、Fujian、中国、361003
        • he First Affiliated Hospital of Xiamen University
        • コンタクト:
          • Jiajie Lin
          • 電話番号:+86-0592-2137569
          • メール:xdfyec@163.com
        • 主任研究者:
          • Qionghua Chen, MD, PHD
    • Guangdong
      • Foshan、Guangdong、中国、528000
        • The First People's Hospital of Foshan
        • コンタクト:
        • 主任研究者:
          • Lijiang Xu, MD, PHD
      • Foshan、Guangdong、中国、528300
        • Foshan Shunde Maternal and Child Health Hospital
        • コンタクト:
        • 主任研究者:
          • Jinzhi Huang, MD, PHD
      • Guangzhou、Guangdong、中国、510280
        • Zhujiang Hospital, Southern Medical University
        • コンタクト:
          • Ethics Office Administrator
          • 電話番号:+86-020-62783372
          • メール:zjyygcp@163.com
        • 主任研究者:
          • Xuefeng Wang, MD, PhD
      • Guangzhou、Guangdong、中国、510010
        • Guangdong Women and Children Hospital
        • コンタクト:
        • 主任研究者:
          • Xiaoli Sun, MD, PHD
      • Guangzhou、Guangdong、中国、510095
        • The Affiliated Cancer Hospital of Guangzhou Medical University
        • コンタクト:
        • 主任研究者:
          • Bin Wen, MD, PhD
      • Guangzhou、Guangdong、中国、510120
        • Guangdong ProvincialHospital of Chinese Medicine
        • コンタクト:
          • Administrator Ethics Committee
          • 電話番号:020-81887233-35943
          • メール:Ilbgs@gzucm.edu.cn
        • 主任研究者:
          • Jing Xiao, MD, PhD
      • Guangzhou、Guangdong、中国、510180
        • Guangzhou First People's Hospital (The Second Affiliated Hospital of South China University of Technology)
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:020-81045412
          • メール:MEC_GZSY@126.com
        • 主任研究者:
          • Yan Kuang, MD, PhD
      • Guangzhou、Guangdong、中国、510317
        • Guangdong Second Provincial GeneralHospital (Guangdong Provincial Emergency Hospital)
        • コンタクト:
          • Administrator Clinical Research Office
          • 電話番号:+86-20-89168338
          • メール:gdech_irb@163.com
        • 主任研究者:
          • Xiafei Fu, MD, PhD
      • Guangzhou、Guangdong、中国、510405
        • The First AffiliatedHospital, Guangzhou University ofTraditional Chinese Medicine
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:+86-20-36588667
          • メール:gztcmlunli@163.com
        • 主任研究者:
          • Sijin Li, MD, PhD
      • Guangzhou、Guangdong、中国、510623
        • Guangzhou Women and Children's Medical Center (The Affiliated Women and Children's Medical Center of Guangzhou Medical University)
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:020-81886332
          • メール:gzwc_irb@163.com
        • 主任研究者:
          • Kun Shi, MD, PhD
      • Guangzhou、Guangdong、中国、511400
        • Panyu Central Hospital Affiliated to Guangzhou Medical University
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:020-34858888
          • メール:pyzxylunli@163.com
        • 主任研究者:
          • Xiang Yang, MD, PhD
      • Shenzhen、Guangdong、中国、518036
        • Peking University Shenzhen Hospital
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:0755-83923333
          • メール:pkuszh_irb@163.com
        • 主任研究者:
          • Zhihong Liu, MD, PhD
      • Shenzhen、Guangdong、中国、518031
        • Shenzhen Maternity and Child Health Hospital
        • コンタクト:
        • 主任研究者:
          • Ping Jin, MD, PHD
      • Zhongshan、Guangdong、中国、510080
        • The First Affiliated Hospital, Sun Yat-sen University
        • コンタクト:
        • 主任研究者:
          • Mian He, MD, PHD
        • 主任研究者:
          • Junxiu Liu, MD, PHD
    • Guangxi
      • Nanning、Guangxi、中国、530021
        • The First Affiliated Hospital of Guangxi Medical University
        • コンタクト:
        • 主任研究者:
          • Jiangtao Fan, MD, PhD
      • Nanning、Guangxi、中国、530000
        • Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital
        • コンタクト:
        • 主任研究者:
          • Chunqiu Xiong, MD, PHD
    • Guangzhou
      • Dongguan、Guangzhou、中国、523000
        • Dongguan Maternal and Child Health Care Hosptial
        • コンタクト:
        • 主任研究者:
          • Ping Zhou, MD, PHD
    • Henan
      • Zhengzhou、Henan、中国、450052
        • The First Affiliated Hospital of Zhengzhou University
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:0371-66278510
          • メール:zdyyllwy@163.com
        • 主任研究者:
          • Liping Han, MD, PhD
    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial People's Hospital)
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:025-68136360
          • メール:jsphkj@163.com
        • 主任研究者:
          • Xiaoling Ma, MD, PhD
    • Jinlin
      • Changchun、Jinlin、中国
        • The First Hospital of Jilin University
        • コンタクト:
        • 主任研究者:
          • Songling Zhang, MD, PHD
    • Liaoning
      • Shenyang、Liaoning、中国、110016
        • The General Hospital of Northern Theater Command of the Chinese People's Liberation Army
        • コンタクト:
          • Ethics Committee Administrator
          • 電話番号:024-28851114
          • メール:btzzyy_irb@163.com
        • 主任研究者:
          • Lipeng Pei, MD, PhD
    • Shanxi
      • Taiyuan、Shanxi、中国、030000
        • Shanxi Provincial People's Hospital
        • コンタクト:
        • 主任研究者:
          • Yuping Suo, MD, PHD
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • The West China Second University Hospital of Sichuan University
        • コンタクト:
        • 主任研究者:
          • Yuedong He, MD, PHD
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310022
        • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
        • コンタクト:
        • 主任研究者:
          • Yichen Wang, MD, PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Voluntarily participate in this clinical study, fully understand the study content, procedures, and potential adverse reactions, and be able to sign the written informed consent form.
  • Able to complete the study in accordance with the study protocol.
  • Subject age ≥18 years.
  • Presence of High-Grade Squamous Intraepithelial Lesion (HSIL) (CIN2 P16 positive/CIN3), specifically: HSIL with histopathological diagnosis of grade II/III (CIN2 P16 positive/CIN3) within 3 months prior to the first treatment.
  • Adequate colposcopy, including: (a) Complete visibility of the cervical transformation zone, including the squamocolumnar junction; (b) Complete visibility of lesion margins.
  • The investigator determines that non-surgical treatment is acceptable for the participant.
  • The investigator determines that the cervical size is suitable for placement of the HAL-PDT device.
  • Meets the following conditions: Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result prior to the start of treatment. No plan for pregnancy during the study period; no sexual activity or use of effective and reliable contraception from the end of the last menstrual period to the start of the study, and agreement to use condoms for barrier contraception during the study period. WOCBP is defined as a female who has experienced menarche, has not undergone hysterectomy or bilateral oophorectomy, and has not reached natural menopause (i.e., no menstruation at all for the past 24 consecutive months).

Exclusion Criteria:

  • Cervical adenocarcinoma in situ or other glandular lesions, invasive cervical cancer, or suspected malignant lesions.
  • CIN2 with P16 negative.
  • Lesions extending to the vaginal wall, cervical canal, or vaginal fornix, or lesions located on the vulva.
  • Prior physical or surgical treatment to the cervix resulting in incomplete cervical structure (e.g., cold knife conization), or receipt of physical or surgical therapy for CIN2 or CIN3 after the current histopathological diagnosis.
  • The first study treatment day falls within 7 half-lives of the last antiviral medication.
  • Severe pelvic inflammatory disease, severe cervicitis, or other severe gynecological infectious diseases found on colposcopic or clinical examination.
  • Investigator judges that vaginal bleeding during treatment may affect treatment outcomes.
  • Receipt of any inactivated vaccine within 2 weeks prior to the first treatment, or any live vaccine within 4 weeks prior to the first treatment.
  • Previous severe cardiovascular, cerebrovascular, neurological, psychiatric, endocrine, or hematopoietic disease that has not been cured; known severely compromised immune function, or need for long-term use of corticosteroids or immunosuppressants; history of malignancy within 5 years.
  • History of clinically significant immunosuppression or confirmed autoimmune disease; or primary immunodeficiency.
  • Known or newly identified active sexually transmitted diseases (STDs), including but not limited to HIV, syphilis, genital herpes, unless adequately treated and tested negative before study treatment.
  • Presence of a cardiac pacemaker.
  • Suspected or known porphyria, or known allergy to the study drug, its chemically similar compounds, or photosensitizers.
  • Allergy to silicone.
  • Pregnant or breastfeeding women.
  • Delivery or miscarriage within 6 weeks prior to enrollment.
  • Participation in any other clinical trial within 30 days prior to study treatment.
  • Poor compliance or judged by the investigator to be unsuitable for participation in this clinical study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Hexaminolevulinate Photodynamic Therapy (HAL-PDT) with Deferred Surgery
Subjects receive Hexaminolevulinate Photodynamic Therapy (HAL-PDT) once every 2 weeks (Q2W) for a total of 6 treatment sessions. At 6 months after the first treatment, participants undergo colposcopy-directed cervical biopsy and HPV testing to assess treatment response. Those who achieve pathological remission (normal or LSIL) enter follow-up without surgery. Those who do not achieve remission (persistent HSIL or disease progression) receive standard surgical treatment (LEEP or CKC) within 4 weeks of the 6-month assessment.
HAL-PDT is a drug-device combination product. The drug is hexaminolevulinate hydrochloride (HAL) 5% ointment. The device is a single-use cervical light delivery device (CL7) with integrated red LEDs. The ointment is applied into the device cup, placed against the cervix for 5 hours of drug absorption, then automatically delivers 125 J/cm² photodynamic therapy for 4 hours and 36 minutes. Total in-situ time is 11-24 hours. Patients remove the device themselves. Treatment regimen: one session every 2 weeks for a total of 6 sessions (Q2W × 6).
アクティブコンパレータ:Immediate Surgery
Participants with histologically confirmed HSIL (CIN2 P16 positive/CIN3) receive standard surgical treatment (LEEP or CKC) per routine clinical practice. Follow-up assessments include HPV testing and colposcopy-directed cervical biopsy at 6 months and 12 months post-surgery to evaluate pathological remission and HPV clearance rates. Safety monitoring is conducted from signing of informed consent through the end of study.
Subjects undergo immediate surgical excision of the cervical lesion via either Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), as determined by the investigator based on the subject's individual lesion characteristics, size, and clinical presentation, following standard institutional surgical protocols.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Histopathological regression rate at 12 months
時間枠:12 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 12 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL)
12 months after the first treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Pathological remission rate at 6 months
時間枠:6 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 6 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL).
6 months after the first treatment
HPV baseline clearance rate at 12 months
時間枠:12 months after the first treatment
Proportion of participants with clearance of baseline high-risk HPV subtypes at 12 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
12 months after the first treatment
Incidence of cervical cancer at 12 months
時間枠:12 months after the first treatment
Proportion of participants with histologically confirmed cervical cancer (any stage) diagnosed within 12 months after the first treatment.
12 months after the first treatment
Human Papillomavirus (HPV) baseline clearance rate at 6 months
時間枠:6 months after the first treatment
Proportion of participants with clearance of baseline high-risk Human Papillomavirus (HPV) subtypes at 6 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
6 months after the first treatment
Quality of life assessed by EORTC QLQ-CX24
時間枠:12 months after the first treatment
Quality of life assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Cervical Cancer Module (EORTC QLQ-CX24). Scores for each domain are linearly transformed to a 0-100 scale. For global health status and functional domains, a higher score indicates a better outcome (better quality of life/function). For symptom scales, a higher score indicates a worse outcome (more severe symptoms).
12 months after the first treatment
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
時間枠:From informed consent through 12 months after the first treatment
Incidence, type, severity (mild, moderate, severe), duration, and relatedness to photodynamic therapy and/or surgical treatment of adverse events (AEs) and serious adverse events (SAEs) occurring from signing of informed consent through the end of study follow-up.
From informed consent through 12 months after the first treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年7月1日

一次修了 (推定)

2029年6月16日

研究の完了 (推定)

2029年6月16日

試験登録日

最初に提出

2026年6月21日

QC基準を満たした最初の提出物

2026年6月21日

最初の投稿 (実際)

2026年6月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月9日

QC基準を満たした最後の更新が送信されました

2026年7月8日

最終確認日

2026年7月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する